Oruka Therapeutics (NASDAQ:ORKA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock, up previously from $42.00.
Oruka Therapeutics (NASDAQ:ORKA) had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a "buy" rating on the stock.
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.